Lifestyle makeover may boost breast cancer treatment success

NCT ID NCT07066189

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a structured nutrition and exercise program can improve the chance of a complete response to pre-surgery chemo-immunotherapy in women with triple-negative breast cancer. About 160 women who are not currently exercising or eating many fruits and vegetables will be randomly assigned to either the lifestyle program or usual care. The goal is to see if those in the program have no cancer remaining in the breast or lymph nodes at the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: exercise and medical nutrition program
What this could lead to: If it works, this could show that a structured lifestyle program helps more women achieve a complete response to pre-surgery treatment for triple-negative breast cancer.
What could go wrong: This is a relatively small, early-stage behavioral trial, so results may not be conclusive or widely applicable. The intervention is added on top of standard treatment, so its independent effect may be hard to measure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Motor Activity Pathologic Complete Response triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Yale University
RECRUITING

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.